PRANDIN repaglinide tablet

Riik: Ameerika Ühendriigid

keel: inglise

Allikas: NLM (National Library of Medicine)

Toimeaine:

REPAGLINIDE (UNII: 668Z8C33LU) (REPAGLINIDE - UNII:668Z8C33LU)

Saadav alates:

Cardinal Health

INN (Rahvusvaheline Nimetus):

REPAGLINIDE

Koostis:

REPAGLINIDE 1 mg

Retsepti tüüp:

PRESCRIPTION DRUG

Volitamisolek:

New Drug Application

Toote omadused

PRANDIN- REPAGLINIDE TABLET
CARDINAL HEALTH
----------
PRANDIN (REPAGLINIDE) TABLETS (0.5, 1, AND 2 MG)
DESCRIPTION
PRANDIN (repaglinide) is an oral blood glucose-lowering drug of the
meglitinide class used in the
management of type 2 diabetes mellitus (also known as non-insulin
dependent diabetes mellitus or
NIDDM). Repaglinide, S(+)2-ethoxy-4(2((3-methyl-1-(2-(1-piperidinyl)
phenyl)-butyl) amino)-2-
oxoethyl) benzoic acid, is chemically unrelated to the oral
sulfonylurea insulin secretagogues.
The structural formula is as shown below:
Repaglinide is a white to off-white powder with molecular formula C
H N O and a molecular
weight of 452.6. PRANDIN tablets contain 0.5 mg, 1 mg, or 2 mg of
repaglinide. In addition each tablet
contains the following inactive ingredients: calcium hydrogen
phosphate (anhydrous), microcrystalline
cellulose, maize starch, polacrilin potassium, povidone, glycerol
(85%), magnesium stearate,
meglumine, and poloxamer. The 1 mg and 2 mg tablets contain iron
oxides (yellow and red,
respectively) as coloring agents.
CLINICAL PHARMACOLOGY
MECHANISM OF ACTION
Repaglinide lowers blood glucose levels by stimulating the release of
insulin from the pancreas. This
action is dependent upon functioning beta (ß) cells in the pancreatic
islets. Insulin release is glucose-
dependent and diminishes at low glucose concentrations.
Repaglinide closes ATP-dependent potassium channels in the ß-cell
membrane by binding at
characterizable sites. This potassium channel blockade depolarizes the
ß-cell, which leads to an
opening of calcium channels. The resulting increased calcium influx
induces insulin secretion. The ion
channel mechanism is highly tissue selective with low affinity for
heart and skeletal muscle.
PHARMACOKINETICS
®
®
27
36
2
4
ABSORPTION: After oral administration, repaglinide is rapidly and
completely absorbed from the
gastrointestinal tract. After single and multiple oral doses in
healthy subjects or in patients, peak plasma
drug levels (C
) occur within 1 hour (T
). Repaglinide is rapidly